{"organizations": [], "uuid": "77497fdb561e81c341b652267ac095994a62a429", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eyegate-pharma-submits-investigati/brief-eyegate-pharma-submits-investigational-device-exemption-amendment-for-second-pilot-study-of-ocular-bandage-gel-idUSFWN1QQ0UX", "country": "US", "domain_rank": 408, "title": "Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-03-08T21:41:00.000+02:00", "replies_count": 0, "uuid": "77497fdb561e81c341b652267ac095994a62a429"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eyegate-pharma-submits-investigati/brief-eyegate-pharma-submits-investigational-device-exemption-amendment-for-second-pilot-study-of-ocular-bandage-gel-idUSFWN1QQ0UX", "ord_in_thread": 0, "title": "Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eyegate pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "novo", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Eyegate Pharmaceuticals Inc:\n* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL\n* EYEGATE PHARMACEUTICALS - SUBMITTED AMENDED IDE APPLICATION TO U.S. FDA FOR A PILOT STUDY OF EYEGATE OCULAR BANDAGE GEL\n* EYEGATE PHARMACEUTICALS INC - AMENDMENT SUMMARIZES CO’S RESPONSES TO FDA’S QUESTIONS AND COMMENTS IN RESPONSE TO ORIGINAL IDE SUBMISSION\n* EYEGATE PHARMACEUTICALS INC - AMENDMENT INCLUDES VALIDATION DATA ON MANUFACTURING PROCESSES AND BIOBURDEN TESTS RELATED TO PRODUCTION OF EYEGATE OBG\n* EYEGATE PHARMACEUTICALS INC - CONTINUE TO MOVE FORWARD TOWARD PLANNED 510(K) DE NOVO FILING IN 2019 FOR EYEGATE OBG Source text for Eikon:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T21:41:00.000+02:00", "crawled": "2018-03-08T16:01:22.000+02:00", "highlightTitle": ""}